Evidence map›Paper›PMID 42201025›Full record

ReviewMedical sciences (Basel, Switzerland)2026

Impact of Variant Allele Frequency (VAF) Levels on Clinical Efficacy of Osimertinib in Patients with Metastatic NSCLC.

Abed Agbarya, Kamel Mhameed, Arina Soklakova, Haitam Nasrallah, Mahmoud Abu Amna, Sabri El-Saied, Mohammad Sheikh-Ahmad, Walid Shalata

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Medical sciences (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Abed AgbaryaThe Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3109601, Israel.ORCID 0000-0002-3330-2959
Kamel MhameedThe Joseph Fishman Oncology Center, Rambam Medical Center, Haifa 3525409, Israel.
Arina SoklakovaMedical School for International Health, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva 8410501, Israel.
Haitam NasrallahThe Joseph Fishman Oncology Center, Rambam Medical Center, Haifa 3525409, Israel.
Mahmoud Abu AmnaThe Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3109601, Israel.ORCID 0000-0003-0571-9287
Sabri El-SaiedFaculty of Health Sciences, Ben Gurion University of the Negev, Ben Gurion Avenue, Beer Sheva 8410501, Israel.
Mohammad Sheikh-AhmadDepartment of Oncology, Bnai-Zion Medical Center, Haifa 3339419, Israel.
Walid ShalataFaculty of Health Sciences, Ben Gurion University of the Negev, Ben Gurion Avenue, Beer Sheva 8410501, Israel.ORCID 0000-0002-7570-4550

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AcrylamidesAniline CompoundsCarcinoma, Non-Small-Cell LungGene FrequencyLung NeoplasmsAntineoplastic AgentsErbB ReceptorsHumansIndolesMutationNeoplasm MetastasisProtein Kinase InhibitorsPyrimidinesTreatment OutcomeAcrylamidesAniline CompoundsAntineoplastic AgentsEGFR protein, humanErbB ReceptorsIndolesosimertinibProtein Kinase InhibitorsPyrimidinescirculating tumor DNA (ctDNA)EGFR tyrosine kinase inhibitor (EGFR TKI)epidermal growth factor receptor (EGFR)liquid biopsynon-small cell lung cancer (NSCLC)osimertinibvariant allele frequency (VAF)

Identifiers

PMID42201025
PMCPMC13214930

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.